与癌症治疗相关的阴道毒性:其患病率和评估方法 - - 一项系统性审查
Marithé Claes1,2,3,4, L Tuts5,6,7,8, J Robijns5,6,7,8
1Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium. marithe.claes@uhasselt.be.
Journal of cancer survivorship : research and practice
|February 22, 2024
概括
癌症治疗导致阴道干燥和狭窄等生殖尿路副作用,特别是在乳腺和妇科癌症患者中. 需要进一步的研究,以改善幸存者的管理和生活质量.
科学领域:
- 在瘤学瘤学.
- 妇科 妇科医生 妇科
- 患者报告的结果
背景情况:
- 癌症影响全球数百万女性,与治疗相关的副作用显著.
- 生殖尿路 (GU) 并发症会影响幸存者的生活质量和性功能.
研究的目的:
- 系统地审查和比较尿生殖系统的不良影响.
- 分析跨癌症类型,治疗和评估方法的副作用.
主要方法:
- 在PubMed Central,SCOPUS和Cochrane图书馆的系统文献搜索.
- 包括前性/后性观察性队列研究和随机对照试验.
- 使用纽卡斯尔-太华尺度或偏差风险2工具进行质量评估.
主要成果:
- 乳腺癌和妇科癌症患者报告的GU副作用最多.
- 阴道干燥是最常见的问题;阴道狭窄是妇科癌症的主要原因.
- 报告的不良事件发生频率和严重程度存在显著差异.
结论:
- 更年期的泌尿生殖综合征在乳腺癌和妇科癌症幸存者中很普遍,通常表现为阴道干燥或狭窄.
- 患者报告的结果指标 (PROM) 经常用于评估.
- 高质量的试验对于关于阴道毒性和改善患者护理的最终结论至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
202
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
202
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Disorders of the Female Reproductive System
361
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
361
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
278
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
278
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346


